1
|
Effect of ethanol and cocaine on [ 11C]MPC-6827 uptake in SH-SY5Y cells. Mol Biol Rep 2021; 48:3871-3876. [PMID: 33880672 PMCID: PMC8172511 DOI: 10.1007/s11033-021-06336-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/02/2021] [Indexed: 10/26/2022]
Abstract
Microtubules (MTs) are structural units in the cytoskeleton. In brain cells they are responsible for axonal transport, information processing, and signaling mechanisms. Proper function of these processes is critical for healthy brain functions. Alcohol and substance use disorders (AUD/SUDs) affects the function and organization of MTs in the brain, making them a potential neuroimaging marker to study the resulting impairment of overall neurobehavioral and cognitive processes. Our lab reported the first brain-penetrant MT-tracking Positron Emission Tomography (PET) ligand [11C]MPC-6827 and demonstrated its in vivo utility in rodents and non-human primates. To further explore the in vivo imaging potential of [11C]MPC-6827, we need to investigate its mechanism of action. Here, we report preliminary in vitro binding results in SH-SY5Y neuroblastoma cells exposed to ethanol (EtOH) or cocaine in combination with multiple agents that alter MT stability. EtOH and cocaine treatments increased MT stability and decreased free tubulin monomers. Our initial cell-binding assay demonstrated that [11C]MPC-6827 may have high affinity to free/unbound tubulin units. Consistent with this mechanism of action, we observed lower [11C]MPC-6827 uptake in SH-SY5Y cells after EtOH and cocaine treatments (e.g., fewer free tubulin units). We are currently performing in vivo PET imaging and ex vivo biodistribution studies in rodent and nonhuman primate models of AUD and SUDs and Alzheimer's disease.
Collapse
|
2
|
Damuka N, Czoty PW, Davis AT, Nader MA, Nader SH, Craft S, Macauley SL, Galbo LK, Epperly PM, Whitlow CT, Davenport AT, Martin TJ, Daunais JB, Mintz A, Solingapuram Sai KK. PET Imaging of [ 11C]MPC-6827, a Microtubule-Based Radiotracer in Non-Human Primate Brains. Molecules 2020; 25:E2289. [PMID: 32414052 PMCID: PMC7287733 DOI: 10.3390/molecules25102289] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 04/24/2020] [Accepted: 05/09/2020] [Indexed: 01/02/2023] Open
Abstract
Dysregulation of microtubules is commonly associated with several psychiatric and neurological disorders, including addiction and Alzheimer's disease. Imaging of microtubules in vivo using positron emission tomography (PET) could provide valuable information on their role in the development of disease pathogenesis and aid in improving therapeutic regimens. We developed [11C]MPC-6827, the first brain-penetrating PET radiotracer to image microtubules in vivo in the mouse brain. The aim of the present study was to assess the reproducibility of [11C]MPC-6827 PET imaging in non-human primate brains. Two dynamic 0-120 min PET/CT imaging scans were performed in each of four healthy male cynomolgus monkeys approximately one week apart. Time activity curves (TACs) and standard uptake values (SUVs) were determined for whole brains and specific regions of the brains and compared between the "test" and "retest" data. [11C]MPC-6827 showed excellent brain uptake with good pharmacokinetics in non-human primate brains, with significant correlation between the test and retest scan data (r = 0.77, p = 0.023). These initial evaluations demonstrate the high translational potential of [11C]MPC-6827 to image microtubules in the brain in vivo in monkey models of neurological and psychiatric diseases.
Collapse
Affiliation(s)
- Naresh Damuka
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (N.D.); (A.T.D.); (M.A.N.); (C.T.W.)
| | - Paul W. Czoty
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Ashley T. Davis
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (N.D.); (A.T.D.); (M.A.N.); (C.T.W.)
| | - Michael A. Nader
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (N.D.); (A.T.D.); (M.A.N.); (C.T.W.)
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Susan H. Nader
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Suzanne Craft
- Department of Internal Medicine-Gerontology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (S.C.); (S.L.M.)
| | - Shannon L. Macauley
- Department of Internal Medicine-Gerontology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (S.C.); (S.L.M.)
| | - Lindsey K. Galbo
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Phillip M. Epperly
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Christopher T. Whitlow
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (N.D.); (A.T.D.); (M.A.N.); (C.T.W.)
| | - April T. Davenport
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Thomas J. Martin
- Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA;
| | - James B. Daunais
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (P.W.C.); (S.H.N.); (L.K.G.); (P.M.E.); (A.T.D.); (J.B.D.)
| | - Akiva Mintz
- Department of Radiology, Columbia University, New York, NY 10016, USA;
| | - Kiran Kumar Solingapuram Sai
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; (N.D.); (A.T.D.); (M.A.N.); (C.T.W.)
| |
Collapse
|
3
|
Putzke J, Spina MG, Büchler J, Kovar KA, Wolf G, Smalla KH. The effects of p-chloroamphetamine, methamphetamine and 3,4-methylenedioxymethamphetamine (ecstasy) on the gene expression of cytoskeletal proteins in the rat brain. Addict Biol 2007; 12:69-80. [PMID: 17407499 DOI: 10.1111/j.1369-1600.2006.00047.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Repeated administration of beta-phenylalkylamines is known to produce neuronal changes in the central and peripheral nervous systems of mammals. It is suggested that various components of the cytoskeleton undergo profound alterations after amphetamine use and misuse, contributing to behavioral changes and neurotoxicity. Here we studied the expression of microtubule-associated protein 2 (MAP2) and beta-actin after repeated intraperitoneal applications with equimolar doses of p-chloroamphetamine (PCA), methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA) in the brain of male Wistar rats. Effective (molecular) pharmacological doses (ED) were derived and used for the calculation of (molecular) pharmacological indices (PI). Besides clear but different dose-response curves on the toxicity of the drugs, in situ hybridization and Western blot analysis revealed that repeated administration of these compounds resulted in different substance- and dose-dependent changes in MAP2 gene expression, e.g. in the frontoparietal somatosensoric cortex. In contrast, the expression of beta-actin was not influenced by any of the compounds at the dose levels tested. Lethal doses were determined with 2.1 (PCA), >5.1 (METH) and 8.4 mg/kg/day (MDMA). Linear and non-linear repeat-dose lethality was observed for MDMA and PCA, respectively, whereas METH was non-lethal in the dose range used. Values for ED(MAP2) were 0.3, 0.52 and >16.8 mg/kg/day, and therefore those for PI(MAP2) were 20, 4, and 0.5 for METH, PCA and MDMA, respectively. Although the results on mortality did not reflect changes in MAP2 gene expression, they suggest a remarkable difference for those amphetamines without substituents or with a halogen atom at the paraposition of the benzene ring, such as METH or PCA, when compared with MDMA-like substances.
Collapse
Affiliation(s)
- Jörg Putzke
- Institute of Medical Neurobiology, OvG-University, Germany.
| | | | | | | | | | | |
Collapse
|
4
|
Iwata M, Muneoka KT, Shirayama Y, Yamamoto A, Kawahara R. A study of a dendritic marker, microtubule-associated protein 2 (MAP-2), in rats neonatally treated neurosteroids, pregnenolone and dehydroepiandrosterone (DHEA). Neurosci Lett 2005; 386:145-9. [PMID: 16002213 DOI: 10.1016/j.neulet.2005.06.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2005] [Revised: 05/27/2005] [Accepted: 06/01/2005] [Indexed: 11/19/2022]
Abstract
Neurosteroids administered during the neonatal period affect the development of several brain systems. We examined the effects of neonatal treatment with pregnenolone and dehydroepiandrosterone (DHEA) on a marker of neuronal dendrites, microtubule-associated protein 2 (MAP-2), in rat brain. Neonatal treatment with pregnenolone and DHEA increased the expression of MAP-2 in the hippocampus and nucleus accumbens but not in the prefrontal cortex, striatum or amygdala in adulthood.
Collapse
Affiliation(s)
- Masaaki Iwata
- Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan
| | | | | | | | | |
Collapse
|